As of Q3 2020, the average sales price (ASP) of autoimmune disease drug Remicade was around 483 U.S. dollars, compared to 457 U.S. dollars for biosimilar Renflexis. This statistic illustrates a comparison of the ASP of Remicade vs biosimilars in the United States.
Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q3 2020
(in U.S. dollars)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Amgen. (October 31, 2022). Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q3 2020 (in U.S. dollars) [Graph]. In Statista. Retrieved November 22, 2024, from https://www.statista.com/statistics/1186626/comparison-asp-remicade-vs-biosimilars-us/
Amgen. "Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q3 2020 (in U.S. dollars)." Chart. October 31, 2022. Statista. Accessed November 22, 2024. https://www.statista.com/statistics/1186626/comparison-asp-remicade-vs-biosimilars-us/
Amgen. (2022). Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q3 2020 (in U.S. dollars). Statista. Statista Inc.. Accessed: November 22, 2024. https://www.statista.com/statistics/1186626/comparison-asp-remicade-vs-biosimilars-us/
Amgen. "Comparison of The Average Sales Price (Asp) of Remicade Vs Biosimilars in The United States as of Q3 2020 (in U.S. Dollars)." Statista, Statista Inc., 31 Oct 2022, https://www.statista.com/statistics/1186626/comparison-asp-remicade-vs-biosimilars-us/
Amgen, Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q3 2020 (in U.S. dollars) Statista, https://www.statista.com/statistics/1186626/comparison-asp-remicade-vs-biosimilars-us/ (last visited November 22, 2024)
Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q3 2020 (in U.S. dollars) [Graph], Amgen, October 31, 2022. [Online]. Available: https://www.statista.com/statistics/1186626/comparison-asp-remicade-vs-biosimilars-us/